|
1
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J and
Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 59:225–249.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Marchetti C, Pisano C, Facchini G, Bruni
GS, Magazzino FP, Losito S and Pignata S: First-line treatment of
advanced ovarian cancer: Current research and perspectives. Expert
Rev Anticancer Ther. 10:47–60. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cohen JG, White M, Cruz A and
Farias-Eisner R: In 2014, can we do better than CA125 in the early
detection of ovarian cancer? World J Biol Chem. 5:286–300. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sopik V, Iqbal J, Rosen B and Narod SA:
Why have ovarian cancer mortality rates declined? Part I.
Incidence. Gynecol Oncol. 138:741–749. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sopik V, Iqbal J, Rosen B and Narod SA:
Why have ovarian cancer mortality rates declined? Part II.
Case-fatality. Gynecol Oncol. 138:750–756. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ahmed N, Oliva K, Rice GE and Quinn MA:
Cell-free 59 kDa immunoreactive integrin-linked kinase: A novel
marker for ovarian carcinoma. Clin Cancer Res. 10:2415–2420. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bagnato A and Rosanò L:
Epithelial-mesenchymal transition in ovarian cancer progression: A
crucial role for the endothelin axis. Cells Tissues Organs.
185:85–94. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ahmed N, Riley C, Oliva K, Stutt E, Rice
GE and Quinn MA: Integrin-linked kinase expression increases with
ovarian tumour grade and is sustained by peritoneal tumour fluid. J
Pathol. 201:229–237. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lössner D, Abou-Ajram C, Benge A,
Aumercier M, Schmitt M and Reuning U: Integrin alphavbeta3
upregulates integrin-linked kinase expression in human ovarian
cancer cells via enhancement of ILK gene transcription. J Cell
Physiol. 220:367–375. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liu Q, Xiao L, Yuan D, Shi X and Li P:
Silencing of the integrin-linked kinase gene induces the apoptosis
in ovarian carcinoma. J Recept Signal Transduct Res. 32:120–127.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Li Q, Li C, Zhang YY, Chen W, Lv JL, Sun J
and You QS: Silencing of integrin-linked kinase suppresses in vivo
tumorigenesis of human ovarian carcinoma cells. Mol Med Rep.
7:1050–1054. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Oloumi A, Maidan M, Lock FE, Tearle H,
McKinney S, Muller WJ, Aparicio SA and Dedhar S: Cooperative
signaling between Wnt1 and integrin-linked kinase induces
accelerated breast tumor development. Breast Cancer Res.
12:R382010. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Oneyama C, Morii E, Okuzaki D, Takahashi
Y, Ikeda J, Wakabayashi N, Akamatsu H, Tsujimoto M, Nishida T,
Aozasa K and Okada M: MicroRNA-mediated upregulation of
integrin-linked kinase promotes Src-induced tumor progression.
Oncogene. 31:1623–1635. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ghahhari NM and Babashah S: Interplay
between microRNAs and WNT/β-catenin signalling pathway regulates
epithelial-mesenchymal transition in cancer. Eur J Cancer.
51:1638–1649. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang H, Fan L, Xia X, Rao Y, Ma Q, Yang J,
Lu Y, Wang C, Ma D and Huang X: Silencing Wnt2B by siRNA
interference inhibits metastasis and enhances chemotherapy
sensitivity in ovarian cancer. Int J Gynecol Cancer. 22:755–761.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sanchez AM, Giorgione V, Viganò P, Papaleo
E, Candiani M, Mangili G and Panina-Bordignon P: Treatment with
anticancer agents induces dysregulation of specific Wnt signaling
pathways in human ovarian luteinized granulosa cells in vitro.
Toxicol Sci. 136:183–192. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liu H, Yan ZQ, Li B, Yin SY, Sun Q, Kou
JJ, Ye D, Ferns K, Liu HY and Liu SL: Reduced expression of SOX7 in
ovarian cancer: A novel tumor suppressor through the Wnt/β-catenin
signaling pathway. J Ovarian Res. 7:872014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Meng J, Zhang D, Pan N, Sun N, Wang Q, Fan
J, Zhou P, Zhu W and Jiang L: Identification of miR-194-5p as a
potential biomarker for postmenopausal osteoporosis. Peer J.
3:e9712015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
da W Huang, Sherman BT and Lempicki RA:
Systematic and integrative analysis of large gene lists using DAVID
bioinformatics resources. Nat Protoc. 4:44–57. 2009.PubMed/NCBI
|
|
21
|
Hsu SD, Tseng YT, Shrestha S, Lin YL,
Khaleel A, Chou CH, Chu CF, Huang HY, Lin CM, Ho SY, et al:
miRTarBase update 2014: An information resource for experimentally
validated miRNA-target interactions. Nucleic Acids Res. 42(Database
Issue): D78–D85. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Thamilselvan V, Craig DH and Basson MD:
FAK association with multiple signal proteins mediates
pressure-induced colon cancer cell adhesion via a Src-dependent
PI3K/Akt pathway. FASEB J. 21:1730–1741. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rosanò L, Cianfrocca R, Tocci P, Spinella
F, Di Castro V, Caprara V, Semprucci E, Ferrandina G, Natali PG and
Bagnato A: Endothelin A receptor/β-arrestin signaling to the Wnt
pathway renders ovarian cancer cells resistant to chemotherapy.
Cancer Res. 74:7453–7464. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mostowska A, Pawlik P, Sajdak S, Markowska
J, Pawałowska M, Lianeri M and Jagodzinski PP: An analysis of
polymorphisms within the Wnt signaling pathway in relation to
ovarian cancer risk in a Polish population. Mol Diagn Ther.
18:85–91. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bonci D, Coppola V, Musumeci M, Addario A,
Giuffrida R, Memeo L, D'Urso L, Pagliuca A, Biffoni M, Labbaye C,
et al: The miR-15a-miR-16-1 cluster controls prostate cancer by
targeting multiple oncogenic activities. Nat Med. 14:1271–1277.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hawkins SM, Creighton CJ, Han DY, Zariff
A, Anderson ML, Gunaratne PH and Matzuk MM: Functional microRNA
involved in endometriosis. Mol Endocrinol. 25:821–832. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Selbach M, Schwanhäusser B, Thierfelder N,
Fang Z, Khanin R and Rajewsky N: Widespread changes in protein
synthesis induced by microRNAs. Nature. 455:58–63. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Xia H, Ng SS, Jiang S, Cheung WK, Sze J,
Bian XW, Kung HF and Lin MC: miR-200a-mediated downregulation of
ZEB2 and CTNNB1 differentially inhibits nasopharyngeal carcinoma
cell growth, migration and invasion. Biochem Biophys Res Commun.
391:535–541. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Cortez V, Nair BC, Chakravarty D and
Vadlamudi RK: Integrin-linked kinase 1: Role in hormonal cancer
progression. Front Biosci (Schol Ed). 3:788–796. 2011.PubMed/NCBI
|
|
30
|
Luo P, Fei J, Zhou J and Zhang W:
microRNA-126 suppresses PAK4 expression in ovarian cancer SKOV3
cells. Oncol Lett. 9:2225–2229. 2015.PubMed/NCBI
|
|
31
|
Guo T, Yu W, Lv S, Zhang C and Tian Y:
miR-302a inhibits the tumorigenicity of ovarian cancer cells by
suppression of SDC1. Int J Clin Exp Pathol. 8:4869–4880.
2015.PubMed/NCBI
|
|
32
|
Fan Y, Fan J, Huang L, Ye M, Huang Z, Wang
Y, Li Q and Huang J: Increased expression of microRNA-196a predicts
poor prognosis in human ovarian carcinoma. Int J Clin Exp Pathol.
8:4132–4137. 2015.PubMed/NCBI
|
|
33
|
Muralidhar GG and Barbolina MV: The
miR-200 Family: Versatile players in epithelial ovarian cancer. Int
J Mol Sci. 16:16833–16847. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Liu R, Liu F, Li L, Sun M and Chen K:
miR-498 regulated FOXO3 expression and inhibited the proliferation
of human ovarian cancer cells. Biomed Pharmacother. 72:52–57. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wen Z, Zhao S, Liu S, Liu Y, Li X and Li
S: MicroRNA-148a inhibits migration and invasion of ovarian cancer
cells via targeting sphingosine-1-phosphate receptor 1. Mol Med
Rep. 12:3775–3780. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Choi YP, Kim BG, Gao MQ, Kang S and Cho
NH: Targeting ILK and β4 integrin abrogates the invasive potential
of ovarian cancer. Biochem Biophys Res Commun. 427:642–648. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wang S and Basson MD: Integrin-linked
kinase: A multi-functional regulator modulating extracellular
pressure-stimulated cancer cell adhesion through focal adhesion
kinase and AKT. Cell Oncol. 31:273–289. 2009.PubMed/NCBI
|
|
38
|
Yoshioka S, King ML, Ran S, Okuda H,
MacLean JA II, McAsey ME, Sugino N, Brard L, Watabe K and Hayashi
K: WNT7A regulates tumor growth and progression in ovarian cancer
through the WNT/β-catenin pathway. Mol Cancer Res. 10:469–482.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Oloumi A, Syam S and Dedhar S: Modulation
of Wnt3a-mediated nuclear beta-catenin accumulation and activation
by integrin-linked kinase in mammalian cells. Oncogene.
25:7747–7757. 2006. View Article : Google Scholar : PubMed/NCBI
|
